NEW ORLEANS -- The targeted factor B inhibitor iptacopan improved hemoglobin (Hb) levels and led to high rates of freedom from transfusion in patients with paroxysmal nocturnal hemoglobinuria (PNH) ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results